Wall Street brokerages expect that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will report earnings per share of ($0.79) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Dova Pharmaceuticals’ earnings. The highest EPS estimate is ($0.75) and the lowest is ($0.87). Dova Pharmaceuticals posted earnings per share of ($0.36) in the same quarter last year, which would indicate a negative year-over-year growth rate of 119.4%. The company is scheduled to report its next earnings report on Thursday, February 21st.

On average, analysts expect that Dova Pharmaceuticals will report full year earnings of ($2.70) per share for the current year, with EPS estimates ranging from ($2.78) to ($2.65). For the next financial year, analysts anticipate that the business will report earnings of ($2.50) per share, with EPS estimates ranging from ($2.90) to ($1.71). Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Dova Pharmaceuticals.

DOVA has been the subject of a number of research reports. LADENBURG THALM/SH SH increased their target price on Dova Pharmaceuticals to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 18th. They noted that the move was a valuation call. JPMorgan Chase & Co. cut Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and lowered their target price for the stock from $34.00 to $20.00 in a report on Wednesday, January 23rd. HC Wainwright began coverage on shares of Dova Pharmaceuticals in a research note on Thursday, December 20th. They set a “buy” rating and a $18.00 price objective for the company. BidaskClub downgraded shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 2nd. Finally, Zacks Investment Research downgraded shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $29.50.

In other Dova Pharmaceuticals news, CEO David Zaccardelli acquired 10,000 shares of Dova Pharmaceuticals stock in a transaction dated Thursday, December 20th. The stock was bought at an average cost of $6.07 per share, for a total transaction of $60,700.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Paul B. Manning acquired 266,631 shares of Dova Pharmaceuticals stock in a transaction dated Thursday, December 20th. The shares were acquired at an average price of $6.17 per share, with a total value of $1,645,113.27. The disclosure for this purchase can be found here. Corporate insiders own 55.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its stake in shares of Dova Pharmaceuticals by 4.9% during the 4th quarter. Bank of New York Mellon Corp now owns 49,907 shares of the company’s stock worth $378,000 after buying an additional 2,313 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Dova Pharmaceuticals by 81.3% during the 2nd quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock worth $159,000 after buying an additional 2,379 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of Dova Pharmaceuticals by 19.8% during the 3rd quarter. Teachers Advisors LLC now owns 21,561 shares of the company’s stock worth $452,000 after buying an additional 3,556 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Dova Pharmaceuticals by 46.1% during the 4th quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock worth $116,000 after buying an additional 4,843 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Dova Pharmaceuticals by 14,705.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 36.90% of the company’s stock.

DOVA stock traded up $0.35 during trading hours on Friday, reaching $7.92. 143,814 shares of the stock were exchanged, compared to its average volume of 186,291. The stock has a market cap of $223.38 million, a PE ratio of -5.66 and a beta of 2.03. The company has a current ratio of 7.50, a quick ratio of 7.40 and a debt-to-equity ratio of 0.17. Dova Pharmaceuticals has a 12 month low of $5.62 and a 12 month high of $37.00.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Read More: What is cost of equity?

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.